Sign In
Buy ANNX
$5.39
+0.130 (+2.47%)
At Close: Jun 03, 2026
Annexon: Mixed Results, Overly Strong Market Reaction
07:21pm, Friday, 14'th Jul 2023
ANNX produced mixed results from its GA program. While the primary endpoint was not met, an important functional endpoint saw success. However, the market reaction was drastic, and perhaps too drastic
Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why
11:55am, Tuesday, 30'th May 2023
Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.
Why Shares of Annexon Are Plummeting Thursday
11:52am, Thursday, 25'th May 2023
Annexon still plans a phase 3 study for therapy ANX007. The first therapy to treat geographic atrophy (GA) was approved by the FDA in February.
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An Edge
09:23am, Sunday, 21'st May 2023
Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%,
May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge
07:47am, Sunday, 14'th May 2023
Two new Breakout Stocks for Week 20 with better than 10% short-term upside, ETF updates, and two Dow 30 Picks. Average cumulative returns for 2023 are +68.3% YTD. The negative MG Signal continues, but
April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge
08:01am, Sunday, 23'rd Apr 2023
April MDA Breakout Stocks/ETFs Week 17 - 2023: High-Frequency Gainers To Give You An Edge.
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
11:30am, Monday, 06'th Mar 2023 GlobeNewswire Inc.
Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023
Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference
11:30am, Monday, 27'th Feb 2023 GlobeNewswire Inc.
BRISBANE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical
Stocks To Watch: Earnings Heat Up, Healthcare Catalysts And M&A Wildcards
03:00pm, Saturday, 21'st Jan 2023 Seeking Alpha
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
09:30pm, Tuesday, 17'th Jan 2023 GlobeNewswire Inc.
BRISBANE, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classica
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
02:00pm, Sunday, 08'th Jan 2023 GlobeNewswire Inc.
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications
Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio
11:30am, Friday, 06'th Jan 2023 GlobeNewswire Inc.
BRISBANE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classica
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
11:30am, Wednesday, 04'th Jan 2023 GlobeNewswire Inc.
BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classica
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
06:30am, Wednesday, 04'th Jan 2023
BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical
Wall Street Analysts Think Annexon, Inc. (ANNX) Could Surge 241%: Read This Before Placing a Bet
02:55pm, Thursday, 01'st Dec 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 241.4% in Annexon, Inc. (ANNX). While the effectiveness of this highly sought-after metric is questionable, the
